A novel treatment for heart failure targets myocardial fibrosis. Scientific Publication

Aug 1, 2021 | Magazine: Nature Medicine

John G F Cleland 1, Pierpaolo Pellicori 2, Arantxa González 3 4

A new trial suggests that pirfenidone, an approved treatment for idiopathic pulmonary fibrosis, may also reduce myocardial fibrosis in patients with heart failure who have a preserved left ventricular ejection fraction.

ARTICLE CITATION Nat Med. 2021 Aug;27(8):1343-1344. doi: 10.1038/s41591-021-01457-9.

see publication in pubmed

Our authors

Dr. Arantxa González Miqueo [SP] Curriculum

Researcher | Principal Investigator Heart Failure Research Group